News and innovation April 29, 2024
EU Directive 2022/431: What’s in it for healthcare workers?
EU Directive 2022/431 in a nutshell European Union (EU) Directive 2022/431, also known as the Carcinogens, Mutagens and Reprotoxic Substances…
EU Directive 2022/431: What’s in it for healthcare workers?
EU Directive 2022/431 in a nutshell European Union (EU) Directive 2022/431, also known as the Carcinogens, Mutagens and Reprotoxic Substances…
Quality control of prefilled flush syringes: key considerations
Before delving into the quality control of prefilled flush syringes, which are an integral part of vascular access management (VAM),…
New clinic study: Reduce hazardous drug contamination with BD
Even in small concentrations, hazardous drug exposure can cause adverse effects such as internal organ damage, genetic mutations, increased rates…
The ins and outs of syringe waste disposal
Plastics are a low-cost, strong and versatile material that can easily be shaped when melted1. Single-use plastics can be replaced…
New nursing guidelines recommend more frequent surface monitoring
Contamination from hazardous drugs (HDs) is a major health concern for healthcare workers (HCWs) in Europe1. Over 12.7 million of…
The European Union reaches a political deal to protect healthcare workers from reprotoxic substances
The members of the European Parliament have secured a deal allowing for the inclusion of reprotoxic substances in the fourth…
How can you protect yourself from the potential hazardous effects of nononcological drugs?
The toxicity of oncological drugs and their potential impact on healthcare worker safety (HCWS) is well known. But what about…
Stop Cancer at Work: Calling the European Commission to act
Occupational cancers claim 100,000 lives in Europe every year and is now the leading cause of work-related deaths.1 Hospital workers…
Cancer care in a COVID-19 climate—Who can make a difference?
From policymakers, to manufacturers, to frontline workers, we all have a role to play in the battle against cancer, but…
Due to their carcinogenicity, mutagenic or reproductive toxicity (CMR), most antivirals, immunosuppressants and anti-neoplastic drugs are considered hazardous. Healthcare professionals…
Fast fact
“I think that the biggest issue in our service is choosing which [vascular access device (VAD)] for which patients,” Professor Caren Randon, MD, PhD